Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

macspred pty. ltd. - metsulfuron-methyl - dry flowable - metsulfuron-methyl urea-sulfonyl active 600.0 g/kg - herbicide - barley | cereal rye | commercial/industrial land | flood plain | natural pasture (native) | right-of-way - general | triticale | - african turnip weed | alligator weed | amsinckia,yellow burrweed or burr grass | apple box | australian or native blackthorn | ball mustard | bellyache bush | bitou bush or boneseed | blackberry | blakely's red gum or gum | bracken | bridal creeper | broadleaf dock | calomba daisy | cape tulip | charlock | chickweed | chicory | crofton weed | cutleaf mignonette | darling pea | deadnettle | denseflower fumitory (red) | dwarf amaranth or boggabri weed | erodium, crowfoot or storksbill | fennel | furze or gorse | golden dodder | great mullein | gum - peppermint | hare's-ear or treacle mustard | hawthorn | inkweed | japanese sunflower | kangaroo thorn | lantana - lantana camara | lincoln weed, sand rocket or mustard | mallee catchfly | medic | messmate stringybark | mimosa pigra | mistflower or creeping crofton weed | new zealand spinach | noogoora burr | parthenium weed | paterson's curse | perennial pigweed | prickly lettuce | privet | ragwort | rough poppy | rubber vine | saltbush or annual saltbush | shepherd

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

radix ablacillia,arnica montana,urtica dioca,stellaria medica,glycyrrhiza glabra

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - bacillus thuringiensis berliner.subsp.israelensis - unknown - bacillus thuringiensis berliner.subsp.israelensis biological-organism-bt-berline active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - bacillus thuringienisis strain ab88 exotoxin, vip3a - unknown - bacillus thuringienisis strain ab88 exotoxin, vip3a active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - bacillus thuringiensis subsp. israelensis - unknown - bacillus thuringiensis subsp. israelensis biological-organism-bt-israele active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - bacillus thuringiensis berliner subsp kurstaki - unknown - bacillus thuringiensis berliner subsp kurstaki biological-organism-bt active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

valent biosciences a div of sumitomo chemical australia - bacillus thuringiensis subsp. aizawai - unknown - bacillus thuringiensis subsp. aizawai biological-organism-bt-aizawai active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - bacillus calmette-guerin substrain tice live antigen (unii: 2xq558l16z) (bacillus calmette-guerin substrain tice live antigen - unii:2xq558l16z) - bacillus calmette-guerin substrain tice live antigen 50 mg - bcg vaccine (tice® strain) is indicated for the prevention of tuberculosis in persons not previously infected with m. tuberculosis who are at high risk for exposure. as with any vaccine, immunization with bcg vaccine may not protect 100% of susceptible individuals. the advisory committee on immunization practices (acip) and the advisory committee for the elimination of tuberculosis has recommended that bcg vaccination be considered in the following circumstances.{3} bcg vaccination is recommended for infants and children with negative tuberculin skin tests who are (a) at high risk of intimate and prolonged exposure to persistently untreated or ineffectively treated patients with infectious pulmonary tuberculosis and who cannot be removed from the source of exposure and cannot be placed on long-term primary preventive therapy, or (b) continuously exposed to persons with infectious pulmonary tuberculosis who have bacilli resistant to isoniazid and rifampin, and the child cannot be separated from the presence of the infectious patient.{3} bcg vaccination of hcws should be considered on an individual basis in settings where (a) a high percentage of tb patients are infected with m. tuberculosis strains resistant to both isoniazid and rifampin, (b) transmission of such drug resistant m. tuberculosis strains to hcws and subsequent infection are likely, and (c) comprehensive tb infection control precautions have been implemented and have not been successful. vaccination should not be required for employment or for assignment of hcws in specific work areas. hcws considered for bcg vaccination should be counseled regarding the risks and benefits associated with both bcg vaccinations and tb preventive therapy.{3} bcg vaccination is not recommended for hcws in settings in which the risk for m. tuberculosis transmission is low.{3} bcg vaccine for prevention of tuberculosis should not be given to persons (a) whose immunologic responses are impaired because of hiv infections, congenital immunodeficiency such as chronic granulomatous disease or interferon gamma receptor deficiency, leukemia, lymphoma, or generalized malignancy or (b) whose immunologic responses have been suppressed by steroids, alkylating agents, antimetabolites, or radiation.{3} bcg vaccine should not be administered to hiv-infected or immunocompromised infants, children, or adults. prior to administration, the possibility of allergic reactions should be assessed. allergy to any component of bcg vaccine or an anaphylactic or allergic reaction to a previous dose of bcg vaccine are contraindications for vaccination. bcg vaccine is not a vaccine for the treatment of active tuberculosis. bcg vaccine should not be used in infants, children, or adults with severe immune deficiency syndromes. children with a family history of immune deficiency disease should not be vaccinated; if they are, an infectious disease specialist should be consulted and anti-tuberculous therapy administered if clinically indicated.{18} please read this leaflet carefully before administering bcg vaccine. the vaccine is to be administered after fully explaining the risks and benefits to the vaccinee, parent, or guardian. bcg vaccination should not be given to individuals previously infected with m. tuberculosis. the sterile, single-use multiple puncture device is for use with the bcg vaccine only. figure 1 figure 2 figure 5 caution: federal law restricts this device to sale by or on the order of a physician. multiple puncture devices may be obtained separately from the order management center, merck sharp & dohme llc, 351 north sumneytown pike, north wales, pa 19454-2505, telephone number: 800-637-2579.

United States - English - NLM (National Library of Medicine)

bella lab co., ltd. - lactobacillus reuteri (unii: 9913i24qee) (lactobacillus reuteri - unii:9913i24qee), sophora flavescens root (unii: iyr6k8kq5k) (sophora flavescens root - unii:iyr6k8kq5k), lavender oil (unii: zbp1yxw0h8) (lavender oil - unii:zbp1yxw0h8), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37) - lactobacillus reuteri 0.6 g in 100 ml - it is one-time female cleaner contained subacidity fermentation extract and natural origin and, hygienic and easy to use. it can help such as improvement odor, skin care, supply moisture and, ph balance. after washing hands, opening individual packaging and removing the y cap. and then applying it to the required area. panty-liner is recommended outside.

United States - English - NLM (National Library of Medicine)

emergent biodefense operations lansing, llc - bacillus anthracis strain v770-np1-r antigens (unii: 873oi62848) (bacillus anthracis strain v770-np1-r antigens - unii:873oi62848) - bacillus anthracis strain v770-np1-r antigens 100 ug in 1 ml - biothrax is a vaccine indicated for the active immunization for the prevention of disease caused by bacillus anthracis in persons 18 through 65 years of age. the efficacy of biothrax for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. do not administer biothrax to individuals with a history of anaphylactic or anaphylactic-like reaction following a previous dose of biothrax or any component of the vaccine, including aluminum, benzethonium chloride, and formaldehyde. [see description (11).] pregnancy category d. [see warnings and precautions (5.3)] healthcare practitioners are encouraged to register women who receive biothrax during pregnancy in emergent’s vaccination pregnancy registry by calling 1-619-553-9255. male fertility: a retrospective study was performed at an in-vitro fertilization clinic to evaluate whether biothrax may impact reproductive function in men. this study compared semen parameters, embryo quality, and pregnancy outcomes in 254 male cli